DBV Technologies to Attend May 2024 Investor Conferences

Montrouge, France, May 9, 2024 — DBV Technologies, a biopharmaceutical firm specializing in treatments for food allergies and other immunologic conditions, has announced that its CEO, Daniel Tassé, will present at two investor conferences in May.

The first event, the Citizens JMP Life Sciences Conference, is scheduled for May 13, 2024, at the Hilton Midtown Hotel in New York. Tassé will engage in a fireside chat at 11:00 am ET. The second event, the H.C. Wainwright BioConnect Conference, will take place on May 20, 2024, at the NASDAQ World Headquarters in New York, where he will again participate in a fireside chat, this time at 12:00 pm ET. Both presentations will be streamed live on the Events page in the Investors section of DBV Technologies' website and will be accessible for replay for 90 days after each event.

DBV Technologies is a clinical-stage biopharmaceutical company developing innovative treatment options for food allergies using its proprietary technology platform, Viaskin™. Food allergies trigger hypersensitive immune reactions that can range from mild symptoms to severe anaphylaxis. With millions affected, including many young children, DBV Technologies focuses on introducing epicutaneous immunotherapy (EPIT™) as a novel non-invasive treatment. This method aims to desensitize the immune system to allergens by delivering microgram quantities of an active compound through intact skin, leveraging the skin’s immune tolerance properties.

The company is currently conducting clinical trials for Viaskin Peanut, targeting peanut allergies in toddlers aged 1 to 3 years and children aged 4 to 7 years. By re-educating the immune system, DBV Technologies aims to transform the care landscape for individuals with food allergies.

DBV Technologies is headquartered in Montrouge, France, and operates in North America from Warren, NJ. Its ordinary shares are listed on segment B of Euronext Paris under the ticker DBV, while its American Depositary Shares (each representing one-half of an ordinary share) trade on the Nasdaq Global Select Market under the ticker DBVT.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!